- Home
- IOVA vs ULCC Comparison
IOVA vs ULCC Comparison
Compare IOVA & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- ULCC
- Stock Information
- Founded
- IOVA 2007
- ULCC 1994
- Country
- IOVA United States
- ULCC United States
- Employees
- IOVA N/A
- ULCC N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- ULCC Air Freight/Delivery Services
- Sector
- IOVA Health Care
- ULCC Consumer Discretionary
- Exchange
- IOVA Nasdaq
- ULCC Nasdaq
- Market Cap
- IOVA 975.1M
- ULCC 1.1B
- IPO Year
- IOVA N/A
- ULCC 2021
- Fundamental
- Price
- IOVA $2.38
- ULCC $5.44
- Analyst Decision
- IOVA Buy
- ULCC Hold
- Analyst Count
- IOVA 11
- ULCC 10
- Target Price
- IOVA $11.90
- ULCC $5.17
- AVG Volume (30 Days)
- IOVA 11.2M
- ULCC 4.5M
- Earning Date
- IOVA 11-06-2025
- ULCC 10-28-2025
- Dividend Yield
- IOVA N/A
- ULCC N/A
- EPS Growth
- IOVA N/A
- ULCC N/A
- EPS
- IOVA N/A
- ULCC N/A
- Revenue
- IOVA $241,525,000.00
- ULCC $3,778,000,000.00
- Revenue This Year
- IOVA $67.40
- ULCC $1.48
- Revenue Next Year
- IOVA $56.32
- ULCC $13.13
- P/E Ratio
- IOVA N/A
- ULCC N/A
- Revenue Growth
- IOVA 636.99
- ULCC 4.60
- 52 Week Low
- IOVA $1.64
- ULCC $2.89
- 52 Week High
- IOVA $12.51
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- IOVA 49.08
- ULCC 61.49
- Support Level
- IOVA $2.27
- ULCC $5.00
- Resistance Level
- IOVA $2.46
- ULCC $5.45
- Average True Range (ATR)
- IOVA 0.14
- ULCC 0.34
- MACD
- IOVA 0.00
- ULCC 0.02
- Stochastic Oscillator
- IOVA 49.09
- ULCC 64.37
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.